Eli Lilly's (LLY) Mirikizumab Meets Crohn's Disease Study Goals
Based on this data, Eli Lilly (LLY) will initiate regulatory submissions worldwide next year seeking regulatory approval for mirikizumab in Crohn's disease.
Lantheus: Fast-Growing Radiotherapeutics Specialist Can Benefit From Lilly's POINT Biopharma Takeover
Lantheus Holdings' stock price has increased more than 1000% since its IPO in 2015, with most gains occurring since 2022. The success of its product PYLARIFY, a PSMA-targeted PET imaging agent for ...
Lilly (LLY) Moves 4.5% Higher: Will This Strength Last?
Lilly (LLY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in ...
Eli Lilly stock hits new high on positive Crohn's disease study results
Eli Lilly and Co (NYSE:LLY) announced on Thursday that its drug development candidate, mirikizumab, met the main goals of a late-stage study to test it as a treatment for moderately to severely act...
Eli Lilly (LLY) stock price is flying: buy the Nvidia of pharma
Eli Lilly (NYSE: LLY) stock price has quietly become one of the best-performing stocks in the past few years. The shares are trading at their all-time high of $605.28, higher than the 2009 low of $14.
Eli Lilly: The GLP-1 Opportunity, While Increasingly Recognized, Is Vastly Underestimated
Eli Lilly is expected to receive FDA approval for tirzepatide, an obesity medication, and has two other medications in phase 3 clinical studies. The GLP-1 therapy market is projected to reach $150 ...
Why Eli Lilly Stock Is Jumping Today
Novo Nordisk announced it's stopping a kidney outcomes trial for Ozempic earlier than planned. Investors are hoping that Novo Nordisk's positive development will translate to success for Lilly.
Eli Lilly gets $14bn boost from Ozempic data - here's what's happened
Eli Lilly and Co (NYSE:LLY) shares were trading 2.6% higher pre-market after a positive read-across from a key trial read-out from its main rival in the weight-loss market. Denmark's Novo Nordisk (...
Why Eli Lilly Stock Crawled Higher Today
According to the results of a recent survey, inclusion of weight-loss drugs is set to ramp up dramatically. More than a few businesses plan to include such coverage in their healthcare insurance po...
Cramer says Vertex has a drug that may address the 'largest market opportunity in the world'
CNBC's Jim Cramer said investors keep an eye on Vertex Pharmaceuticals (VRTX) as the company develops a non-opioid pain drug.
Eli Lilly, McKesson, Novartis Flash Promising Chart Action
Although healthcare stocks lag other sectors, large-cap leaders such as Eli Lilly & Co. NYSE: LLY, McKesson Corp. NYSE: MCK and Novartis AG NYSE: NVS are in possible buy ranges as they get moving...
3 No-Brainer Growth Stocks to Buy in October
Eli Lilly is crushing the market because of its impressive product lineup and strong prospects. Novo Nordisk is just getting warmed up with a massive opportunity for Ozempic and Wegovy.
Eli Lilly pipeline of obesity treatments is positioned to pay off beyond just Mounjaro, analysts say
Shares of Eli Lilly and Co (NYSE:LLY) rose Friday after analysts at Bank of America reaffirmed its confidence in the company. The firm reiterated its Buy rating and upped its price target to $700 f...
Should You Sell This Stock After Another Regulatory Headwind?
Eli Lilly set out to launch four new products this year, but it is unlikely to do so. The company's regulatory roadblocks aren't deal-breakers for its medicines.
Here's the Best Big Pharma Stock of the Decade so Far (and It's Not Even Close)
There have been relatively few big winners among pharma stocks so far in the 2020s. One big pharma stock stands out as the clear leader by roughly tripling over the last nearly four years.
Related Companies